---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-041009"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2023-04-03T23:59:59+00:00"
generated_at: "2026-06-17T06:55:36.467000+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio enters $50M ATM equity offering with BofA and ThinkEquity

## Summary
- Up to $50M of common stock may be sold through BofA Securities and ThinkEquity as sales agents.
- Sales agents will receive commission up to 2.0% of gross proceeds; customary indemnification provided.
- Shares sold at market prices in ordinary brokers' transactions; no minimum obligation to sell.
- Offering is made under existing shelf registration statement (File 333-252625) and prospectus supplement dated March 31, 2023.
- Agreement may be terminated by either party; no assurance of any sales.

## SEC filing metadata
- accession: 0001104659-23-041009
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2023-04-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465923041009/0001104659-23-041009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465923041009/tm2311180d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-041009
- JSON: https://secwatch.observer/filing/0001104659-23-041009.json
- Plain text: https://secwatch.observer/filing/0001104659-23-041009.txt

## Key facts
- Material Agreements
  Annovis Bio, Inc. entered into Sales Agreement with BofA Securities, Inc. and ThinkEquity LLC valued at up to $50.0 million (effective 2023-03-31).
  - Action: entry
  - Agreement: atm program
  - Counterparty: BofA Securities, Inc. and ThinkEquity LLC
  - Value: up to $50.0 million
  - Effective: 2023-03-31
  source text: On March 31, 2023, Annovis Bio, Inc. (the “Company”), entered into an ATM Equity Offering Sales Agreement SM (the “Sales Agreement”) with BofA Securities, Inc. (“BofA”) and ThinkEquity LLC (“ThinkEquity” and, together with BofA, the “Sales Agents”), as sales agents, pursuant to which the Company may offer and sell, from time to time through the Sales Agents, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $50.0 million (the “Shares”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1477845/000110465923041009/0001104659-23-041009-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.